INTRODUCTION
The advent of total parenteral nutrition (TPN) has contributed to improved survival of premature infants and has become a mainstay of modern neonatal care. Unfortunately, as other practices and therapies in the NICU, parenteral nutrition has associated limitations and complications, primarily due to its toxicity to the liver. [1] [2] [3] The risk of developing total parenteral nutrition-associated cholestasis (TPN-C) in neonates requiring parenteral nutrition remains high, especially in premature infants that require TPN for more than 2 weeks and are less than 1000 g birth weight.
1 This group of extremely low birth weight infants (ELBW) has been reported to have a variable incidence of TPN-C that can be as high as 50%. TPN-C can progress to portal fibrosis and irreversible cirrhosis if continued for a prolonged period of time. The worst clinical outcomes have been reported in infants that cannot tolerate any enteral feedings. 4 Several reviews describe demographic, clinical and metabolic/ nutritional factors contributing to TPN-C such as prematurity, duration of TPN, sepsis, immature enterohepatic circulation, enteral starvation, excess or deficiency of aminoacids and mineral/ trace elements, energy overload and/or increased levels of toxic bile salts. [5] [6] [7] [8] Moreover, most reports conclude that the development of TPN-C is multifactorial and that the exact etiology is not completely determined. However, the impact of uteroplacental insufficiency and subsequent intrauterine growth restriction (IUGR) upon the development of this complication has not been reported.
Intrauterine growth is one of the most important indicators of fetal well-being. Growth-restricted fetuses are at risk for intrauterine mortality and postnatal morbidities. 9, 10 Uteroplacental insufficiency alters a number of metabolic and physiologic variables in the fetus, which probably affect the hepatocyte function and tolerance to feedings in the very preterm infant. [11] [12] [13] We therefore hypothesized that ELBW infants with IUGR would have an increased incidence of TPN-C and chronic liver failure when compared to appropriate for gestational age (AGA) ELBW infants.
SUBJECTS AND METHODS Patients
We performed a retrospective review of all ELBW infants (birth weight < 1000 g) that received TPN for more than 7 days in the Neonatal Intensive Care Unit (NICU) at Cedars-Sinai Medical Center. We reviewed the data of the eligible infants from January 1, 1998 until December 31, 2000. The study patients were divided into two groups according to growth (birth weight) plotted against gestational age (GA): appropriate for GA (AGA) and small for GA (SGA: infants weighted less than 10th percentile). GA was based on best obstetrical estimate and by postnatal exam. For this study, all SGA-ELBW had a history of intrauterine growth restriction, and infants with a genetic syndrome or a congenital infection were excluded. IRB approval was obtained to review the records of all the patients.
TPN Cholestasis
Based on previous reports, TPN Cholestasis (TPN-C) was defined as direct bilirubin greater than 2.0 mg/dl that developed during the course of TPN therapy and that was not associated with other known causes for cholestasis. 8 Infants with cholestasis due to a documented genetic or metabolic disorder, infection (TORCH) or extrahepatic obstruction were excluded. In infants with TPN-C, we analyzed the number of TPN days, serum maximum direct bilirubin concentration and bilirubin values at the time of follow up. All ELBW infants, by protocol, received ''trophic GI stimulation'' (i.e.: 1 ml q 4 to 6 hours) within 60 hours of age or so. The age at which feedings were first sustained and the number of episodes of feeding intolerance were analyzed. We defined the first sustained feeding age as the age at which infants were able to tolerate enterally at least half of their total daily intake and when such feeding volume was being increased steadily at least 20 ml/kg daily, until reaching full feeds (120 to 160 ml/kg/day). The infants received either human milk or Enfamil Premature Formula (Mead-Johnson Nutritional Division, Evansville, IN) if the mothers had inadequate milk production. After reaching full feeds, breast milk was fortified using one packet of human milk fortifier added to 25 ml of human milk (Enfamil s Human Milk Fortifier, Mead Johnsons Nutritionals, IN). Feeding intolerance was defined as a gastric residual obtained at 2 hours postinfusion that was greater than 20% of the volume of feeds or the presence of green bilious residual. We also analyzed the amount of protein (g/kg/day), intravenous lipids (g/kg/day) and glucose (mg/kg/minute) that each infant received from the TPN as well as the caloric intake. Other conditions analyzed were necrotizing enterocolitis, bowel surgery and sepsis.
Total Parenteral Nutrition Protocol TPN Protocol was given according to the NICU protocol over 24 hours. ELBW infants are routinely started on parenteral nutrition as soon as electrolyte and fluid balance status have stabilized, usually within 60-72 hours after birth. The indications for more prolonged TPN (>7 days) in our study group were ELBW premature infants that could not be maintained entirely on feedings due to several aspects of prematurity, including slow advancement of enteral feedings, necrotizing enterocolitis, sepsis and/or severe respiratory distress syndrome. Once established the need for prolonged TPN (>7 days), a central line (PICC line or Broviac) would be inserted so as to provide adequate caloric intake. If a UVC was initially placed it was accepted in a central position (IVC above the diaphragm, below the heart).
Protein (Trophamine s , Braun) Infants were started at 0.5 g/kg/ day and the dose was increased by 0.5 g/kg/day increments every day to a maximum dose of 2.5 g/kg/day. Cysteine was added to the solution as tolerated (40 mg cysteine per gram of Trophamine) up to a maximum of 100 mg/kg/day.
Carbohydrates Sufficient glucose to provide adequate calorie intake was also provided. The percent dextrose was adjusted daily, according to the baby's tolerance, not exceeding 20 mg/kg/minute. The daily dextrose increment amount in infants <1000 g, was 0.5% and in infants >1000 g was 1%.
Electrolytes The essential electrolytes that were delivered and monitored on an individual basis were: sodium (sodium chloride and/or sodium acetate), potassium (potassium chloride and/or potassium phosphate), chloride, calcium (administered as a 10% solution of calcium gluconate), phosphorus (calcium to phosphorus ratio in the parenteral nutrition was 1.7) and magnesium.
Vitamins and trace elements A standard multivitamin (Infuvitet Pediatric, Baxter, IL) and trace element supplement was used. In this protocol, trace elements (zinc, copper, manganese, and chromium) were supplied as P.T.E.-4 s (American Pharmaceutical Partners, Inc., CA) with the addition of selenium. The daily dose of P.T.E-4 was 0.2 ml/kg/day. Zinc, chromium and selenium are excreted mainly via the urinary tract and toxic levels of these elements may accumulate in patients with decreased renal function. Therefore, zinc, chromium and selenium were omitted from the i.v. solution if the serum creatinine was >1.2 mg/dl. Copper and manganese intake were decreased or discontinued if the infant developed cholestatic liver disease.
Intravenous lipids Intravenous lipids (Intralipid 20%, Cutter
Laboratories, Berkeley, CA) were also given following the NICU guideline for infants <1000 g. Lipids were started at 0.5 g/kg/day. on day of life 3 to 5 providing acute respiratory problems, sepsis, shock or hyperbilirubinemia approaching exchange levels were under control. Then, they were advanced at a dose of 0.5 g/kg every 2 to 3 days to a maximum of 3 g/kg/day.
In all infants receiving intralipids, we monitored triglycerides levels prior to advancing doses, then weekly. The goal was to maintain triglycerides levels <140 mg/dl. Intralipid doses were given over 24 hours with a low dose of heparin (<135 U/day).
Statistical Analysis
Statistical analysis was performed using Student's t-test, Fisher's exact test and w 2 analysis as appropriate. When there was no evidence for heterogeneity of variance, the adjusted degrees of freedom t-test (Scatterthwaite) was used. 95% Confidence intervals are given for odds ratios. p-values are given for group comparisons. Results are expressed as mean±SD and range or number (%).
RESULTS
Among 1768 infants admitted to the NICU during the study period (January 1, 1998 to December 31, 2000), there were 114 ELBW infants of whom 103 received TPN for more than 7 days; 38 (36%) of them developed TPN-C. The remainder 11 ELBW infants died within the first 10 days of life and are not included in the study since none of them reached the >7 day TPN inclusion criteria. Table 1 shows the characteristics of all 103 ELBW infants that received TPN >7 days. There were no significant differences between the AGA and SGA groups regarding gender, racial distribution, incidence of death and age at which death occurred. However, SGA infants had smaller birth weights in spite of being more mature. This difference in weight and GA reached significance when compared to AGA infants (715±168 vs 810±130 g; p ¼ 0.002 and 28±2 vs 25.7±1.7 weeks; p<0.001). Table 2 represents the characteristics of infants that developed TPN-C. Among 69 AGA-ELBW infants, 19 (27%) developed TPN-C compared to 19 out of 34 SGA-ELBW infants (56%). This TPN-C incidence is statistically significant (odds ratio (OR) ¼ 3.3, p<0.0009; 95% confidence interval (CI) ¼ 1.3 to 8.5).
There was no significant difference in terms of birth weight, racial and sex distribution between the two groups. Again, the SGA group of infants was more mature when compared to AGA infants (28.6±1.9 vs 25±1.7 weeks, p<0.0001). Among the infants that developed TPN-C, eight ELBW infants (four AGA/four SGA) did not survive. The cause of death was liver failure leading to portal hypertension (two AGA/three SGA), respiratory failure (one AGA) and sepsis (one AGA/one SGA). Their liver biopsies and/or autopsies showed extensive sinusoidal/portal fibrosis compatible with ''TPN lesion''. There was no significant difference in the incidence of death between the two groups. However, SGA infants died at a later age (167.5±25 vs 148.5±40 days; p ¼ 0.0456). In the other 30 infants with TPN-C, liver function eventually returned to normal after TPN discontinuation, as confirmed by follow-up serum bilirubin levels measured at time of follow-up (Table 3) .
The onset of direct hyperbilirubinemia was preceded by sepsis (8 days) in one SGA patient, by bowel surgery for perforation in four AGA infants and by necrotizing enterocolitis in two SGA patients (not shown in tables).
In the ELBW infants that developed TPN-C, the characteristics of the TPN infusion, age at which full enteral feedings were reached and episodes of feeding intolerance, as well as the onset of cholestasis, maximum direct bilirubin and last serum bilirubin (checked during outpatient follow-up) are shown in Table 3 . Maximum direct bilirubin values, days on TPN and bilirubin values at the time of follow-up were similar in both groups. However, the onset of TPN-C (number of days that the infant received TPN before direct hyperbilirubinemia was detected) was statistically significant when comparing the two groups, starting earlier in the SGA-ELBW group of infants (20±13 days in SGA days of life, p< 0.0001) and had a higher number of feeding intolerance episodes (16.5±3.6 vs 9.6±3.4 episodes, p<0.0001) when compared to ELBW-AGA babies. There was no significant difference between the amount of protein and total calories received by the two groups. However, in ELBW-SGA infants, the maximum dextrose and lipid intake ever received was significantly higher when compared to ELBW-AGA infants.
DISCUSSION
The purpose of this study was to determine whether intrauterine growth restriction (IUGR) was associated with increase incidence of TPN-C and chronic liver failure in ELBW infants. Although IUGR is not always synonymous of SGA, most SGA infants are malnourished. In our study, all SGA infants had an obstetrical history of IUGR. When compared to less mature AGA-ELBW infants, SGA-ELBW infants who received TPN >7 days had an increased risk for TPN-C.
Maximum direct bilirubin and days on TPN were similar in both groups. However, the onset of cholestasis was significantly different, with an increase in direct bilirubin >2 mg/dl detected at earlier stages of TPN administration in SGA-ELBW infants.
Also, SGA-ELBW infants had more episodes of feeding intolerance and were able to sustain enteral feedings later in life when compared to AGA-ELBW infants.
Although liver enzyme changes and hyperbilirubinemia persisted for weeks to months after TPN was discontinued, there was a gradual normalization of hepatic function in both groups of infants as indicated by bilirubin values at the time of follow-up. The values indicated in this study are the latest laboratory results found for each patient at the time of follow-up. A limitation of this study is that follow-up and monitoring of bilirubin levels varied from child to child.
In two previous studies, Boehm et al. 12, 13 compared the tolerance to protein intake between SGA-and AGA-ELBW infants. SGA infants had a decreased capacity to utilize or metabolize protein during the first postnatal weeks of life. SGA-ELBW infants were also more sensitive to an excessive protein load when compared to AGA-ELBW infants. They conclude that intrauterine growth restriction can cause hepatocellular dysfunction, and this could be reflected in the observed differences in the metabolic capacity to handle protein between AGA and SGA infants. Our two ELBW groups (AGA and SGA) received similar amount of protein from the TPN. The BUN was not significantly different between the two groups; however, there was a trend to higher values in SGA-ELBW infants.
A significant cause of IUGR is uteroplacental insufficiency secondary to maternal morbidities such as hypertension. This condition alters a number of physiologic variables (metabolic fuel availability and gaseous exchange) that affect fetal growth. But the exact mechanisms are not completely understood, specially the impact at the cellular metabolic level.
The IUGR fetal rat has reduced hepatic ATP levels and increased cytosolic and decreased mitochondrial NAD þ /NADH ratios.
14 Changes in gene expression of a number of hepatic enzymes involved in numerous metabolic functions were identified, suggesting an adjustment by the hepatocyte to ensure survival during postnatal life. Moreover, using an IUGR rat model, Lane et al. 15 demonstrated that uteroplacental insufficiency and subsequent IUGR in the rat would lead to altered hepatic fatty acid metabolism. Interestingly, carnitine palmitoyltransferase (CPT1), a key fatty acid-metabolizing enzyme was decreased both in the fetal, juvenile and adult IUGR rat.
In this present study, SGA infants received a higher maximum daily dose of intralipids when compared to AGA infants. Triglycerides levels were routinely monitored and were within the accepted range described in our TPN protocol in both groups, indicating good tolerance at least at this stage of life. Long-term follow-up of this ELBW-SGA cohort into adulthood would be of great interest so as to assess the possible development of adult dyslipidemia associated with IUGR neonates as described by Barker. 16 For this study, the percent dextrose was adjusted daily, according to the baby's tolerance, not exceeding 20 mg/kg/minute to avoid fatty infiltration of the liver. There was a significant difference between both groups regarding the maximum daily dextrose intake from the TPN. ELBW-SGA infants received higher maximum glucose (1.2 mg/kg/min)than the ELBW-AGA group, probably to be provided with more calories.
Li et al. 17 demonstrated that increasing dextrose concentrations in total parenteral nutrition (TPN) causes alterations in hepatic morphology and plasma levels of insulin and glucagon in adult rats. Portal and peripheral insulin levels and periportal fatty infiltration increased in a linear fashion with increasing dextrose concentration. These results suggest that the liver's response to altered portal insulin/glucagon ratio may play an important role in changes of hepatic morphology associated with TPN.
Lane et al. 18 measured glucose uptake and metabolism in the liver of control (sham operated) and IUGR fetal (day 20) and postnatal (1, 4, 14 and 21 days) rats. GLUT-1 is the major glucose transporter in the fetus whereas GLUT-2 is the predominant isoform in the adult liver. In this study, glucose uptake and GLUT-1 protein and mRNA levels were increased whereas GLUT-2 protein and mRNA levels were decreased in IUGR fetal and neonatal liver in contrast to controls. The authors concluded that the metabolic and physiological factors that cause IUGR also alter glucose transporter expression in fetal liver. This alteration may contribute to the abnormal glucose homeostasis in IUGR infants.
The overall mortality in our two groups is lower than the mortality reported by Lee et al. in a study that assessed perinatal management and neonatal outcomes of IUGR (<1000 g) premature infants. 19 In this study, ELBW-IUGR infants (birth weight: 689±181; GA: 30±2) had a mortality of 22% and the ELBW AGA infants (birth weight: 707±179; GA: 24±2) used as control had a mortality of 47%. This difference could be explained by the fact that our AGA-ELBW group mean GA was 26 ± 2 weeks (2 weeks older in average than the Lee's control group). Among the morbidities described in Lee's report, IUGR infants that had more feeding intolerance and received TPN for a longer period of time had a poor prognosis for survival. However, this report does not analyze the incidence of TPN-C or other liver morbidities.
In our population, when we analyzed the infants that developed TPN-C in terms of survival, SGA-ELBW babies had the same incidence of mortality (4/19) than AGA-ELBW infants (4/19) , but died at a later age.
Our data suggest that hepatocellular and GI function is most likely influenced by factors that induce IUGR such as uteroplacental insufficiency. This could result in a reduced liver metabolic capacity, and could lead to a higher incidence of TPN-C in SGA-ELBW infants. Although we did not find increased incidence in liver failure and/or mortality in this group of IUGR infants, the long-term consequences of this complication are not known. Thus, the metabolic differences between SGA and AGA infants should be considered in the nutritional management of ELBW infants.
